TRAFALGAR INTERNATIONAL, INC.

GCAN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item Jun 2021 Jun 2020 Sep 2019 Jun 2018 Mar 2018 Sep 2017 Jun 2017
Revenue $12.6K $48.0K $2.6K $22.5K $136 $136 $73
Cost of Revenue $12.7K $48.1K $72 $66 $43
Gross Profit $-25 $-46 $14.0K $72.9K $70 $30
Gross Margin -0.2% -0.1% 62.3% 53,611.8% 51.5% 41.1%
Operating Expenses
Research & Development
SG&A Expense
Operating Income $-62.5K $-81.9K $-78.4K $22.3K $72.6K $-39.2K $-31.9K
Operating Margin -494.6% -170.5% -2,993.9% 99.3% 53,354.4% -28,856.6% -43,656.2%
Interest Expense $2.2K $1.6K $-750 $1.0K
Pretax Income $-39.0K $1.1M $-126.4K $22.3K $78.5K
Income Tax Expense
Net Income $-39.0K $1.1M $-126.4K $22.3K $78.5K $-80.4K $-164.7K
Net Margin -308.5% 2,294.7% -4,825.6% 99.3% 57,694.9% -59,114.7% -225,642.5%
EPS (Basic) $0.00 $0.01 $0.00 $0.00 $0.00 $0.00 $-0.01
EPS (Diluted) $0.00 $0.01 $0.00 $0.00 $0.00 $0.00 $-0.01
Shares Outstanding (Basic) 478.6M 88.3M 35.4M 29.4M 29.4M 29.4M
Shares Outstanding (Diluted) 478.6M 88.3M 35.4M 29.4M 29.4M 29.4M
Dividends Per Share